Recombinant NAPc2

Drug Profile

Recombinant NAPc2

Alternative Names: NAPc2; Nematode Anticoagulant Protein c2; Recombinant Nematode Anticoagulant c2; rNAPc2

Latest Information Update: 12 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon Corporation
  • Class Anticoagulants; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Colorectal cancer; Deep vein thrombosis; Disseminated intravascular coagulation; Ebola virus infections

Most Recent Events

  • 10 Dec 2014 Recombinant NAPc2 receives Orphan Drug status for Ebola virus infections in USA
  • 10 Dec 2014 rNAPc2 is available for licensing as of 05 Oct 2012. www.arcabiopharma.com
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top